Author:
Yanagi Yasuo,Takahashi Kanji,Iida Tomohiro,Gomi Fumi,Morii Junko,Kunikane Eriko,Sakamoto Taiji
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Yanagi Y, Aihara Y, Fukuda T, Hashimoto H. Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration in Japan. Nippon Ganka Gakkai Zasshi (J Jpn Ophthalmol Soc). 2011;115:825–31 (in Japanese).
2. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291(15):1900–1.
3. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–16.
4. Yasuda M. Observational study (cohort study): the Hisayama study. J Eye. 2009;26(1):25–30 (in Japanese).
5. Mathenge W. Age-related macular degeneration. Community Eye Health. 2014;27(87):49–50.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献